JP4461179B2 - Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン - Google Patents

Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン Download PDF

Info

Publication number: JP4461179B2
Authority: JP; Japan
Prior art keywords: cells; hla; peptide; urlc10; ttk
Prior art date: 2005-02-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP2007531118A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008530975A (ja

JP2008530975A5 (2

Inventor

秀晃田原

卓也角田

祐輔中村

弥太郎醍醐

修一中鶴

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Oncotherapy Science Inc

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-02-25

Filing date

2006-02-17

Publication date

2010-05-12

2006-02-17 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2008-08-14 Publication of JP2008530975A publication Critical patent/JP2008530975A/ja

2009-05-28 Publication of JP2008530975A5 publication Critical patent/JP2008530975A5/ja

2010-05-12 Application granted granted Critical

2010-05-12 Publication of JP4461179B2 publication Critical patent/JP4461179B2/ja

2026-02-17 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims description 211
208000020816 lung neoplasm Diseases 0.000 title claims description 57
206010058467 Lung neoplasm malignant Diseases 0.000 title claims description 56
201000005202 lung cancer Diseases 0.000 title claims description 56
102000004196 processed proteins & peptides Human genes 0.000 title description 115
102100037920 Insulin-like growth factor 2 mRNA-binding protein 3 Human genes 0.000 title description 62
101100452137 Homo sapiens IGF2BP3 gene Proteins 0.000 title description 57
229920001184 polypeptide Polymers 0.000 title description 25
229940023041 peptide vaccine Drugs 0.000 title 1
206010028980 Neoplasm Diseases 0.000 claims description 58
108010013476 HLA-A24 Antigen Proteins 0.000 claims description 54
239000000427 antigen Substances 0.000 claims description 28
102000036639 antigens Human genes 0.000 claims description 28
108091007433 antigens Proteins 0.000 claims description 28
125000003275 alpha amino acid group Chemical group 0.000 claims description 22
210000001808 exosome Anatomy 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 4
210000004027 cell Anatomy 0.000 description 148
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 141
230000001472 cytotoxic effect Effects 0.000 description 58
101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 description 57
102100036109 Dual specificity protein kinase TTK Human genes 0.000 description 54
238000000034 method Methods 0.000 description 46
210000000612 antigen-presenting cell Anatomy 0.000 description 41
201000011510 cancer Diseases 0.000 description 40
-1 URLC10 Proteins 0.000 description 31
101100279953 Arabidopsis thaliana ERECTA gene Proteins 0.000 description 30
101150105790 TE1 gene Proteins 0.000 description 30
150000001413 amino acids Chemical class 0.000 description 28
108090000623 proteins and genes Proteins 0.000 description 28
229940024606 amino acid Drugs 0.000 description 27
238000007792 addition Methods 0.000 description 23
210000001744 T-lymphocyte Anatomy 0.000 description 22
230000000694 effects Effects 0.000 description 20
230000001939 inductive effect Effects 0.000 description 20
210000004443 dendritic cell Anatomy 0.000 description 19
230000002285 radioactive effect Effects 0.000 description 18
238000011282 treatment Methods 0.000 description 18
230000002163 immunogen Effects 0.000 description 17
210000004881 tumor cell Anatomy 0.000 description 17
229960005486 vaccine Drugs 0.000 description 17
230000005809 anti-tumor immunity Effects 0.000 description 14
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 14
230000006698 induction Effects 0.000 description 13
239000013598 vector Substances 0.000 description 12
238000003556 assay Methods 0.000 description 11
230000014509 gene expression Effects 0.000 description 11
239000000463 material Substances 0.000 description 11
239000000203 mixture Substances 0.000 description 10
230000003013 cytotoxicity Effects 0.000 description 9
231100000135 cytotoxicity Toxicity 0.000 description 9
230000028993 immune response Effects 0.000 description 9
238000009169 immunotherapy Methods 0.000 description 9
238000000338 in vitro Methods 0.000 description 9
102000004169 proteins and genes Human genes 0.000 description 9
239000012636 effector Substances 0.000 description 8
230000002265 prevention Effects 0.000 description 8
239000002671 adjuvant Substances 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000003814 drug Substances 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
238000006467 substitution reaction Methods 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
108010002350 Interleukin-2 Proteins 0.000 description 6
230000000903 blocking effect Effects 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
231100000433 cytotoxic Toxicity 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 5
108010075704 HLA-A Antigens Proteins 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
229940022399 cancer vaccine Drugs 0.000 description 5
238000009566 cancer vaccine Methods 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
239000000047 product Substances 0.000 description 5
230000004044 response Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 4
102100025947 Insulin-like growth factor II Human genes 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical group C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108050005900 Signal peptide peptidase-like 2a Proteins 0.000 description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Chemical group C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
229940068935 insulin-like growth factor 2 Drugs 0.000 description 4
229930182817 methionine Chemical group 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
239000000126 substance Substances 0.000 description 4
108700028369 Alleles Proteins 0.000 description 3
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
206010027476 Metastases Diseases 0.000 description 3
108700020796 Oncogene Proteins 0.000 description 3
101710160107 Outer membrane protein A Proteins 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
230000005975 antitumor immune response Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000012258 culturing Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000012634 fragment Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
210000000987 immune system Anatomy 0.000 description 3
230000002147 killing effect Effects 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
230000009401 metastasis Effects 0.000 description 3
238000012775 microarray technology Methods 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
238000002255 vaccination Methods 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 2
101100182729 Homo sapiens LY6K gene Proteins 0.000 description 2
101710126182 Insulin-like growth factor 2 mRNA-binding protein 3 Proteins 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
108010002586 Interleukin-7 Proteins 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108010046117 N-palmitoyl-5,6-dipalmitoyl-S-glycerylcysteinyl-seryl-serine Proteins 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229940037003 alum Drugs 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000003100 immobilizing effect Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
239000002502 liposome Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000002493 microarray Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000002433 mononuclear leukocyte Anatomy 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000002245 particle Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000037452 priming Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
238000013519 translation Methods 0.000 description 2
230000014616 translation Effects 0.000 description 2
XVQKZSLOGHBCET-INVHGPFASA-N tripalmitoyl-S-glyceryl-cysteinyl-seryl-serine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O)CSCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC XVQKZSLOGHBCET-INVHGPFASA-N 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
241001227713 Chiron Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
108010086377 HLA-A3 Antigen Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
101150057353 Ttk gene Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003091 anti-genotoxic effect Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
102000015736 beta 2-Microglobulin Human genes 0.000 description 1
108010081355 beta 2-Microglobulin Proteins 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
208000037887 cell injury Diseases 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000016396 cytokine production Effects 0.000 description 1
230000002074 deregulated effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000011223 gene expression profiling Methods 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000002998 immunogenetic effect Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
102000033952 mRNA binding proteins Human genes 0.000 description 1
108091000373 mRNA binding proteins Proteins 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000000693 micelle Substances 0.000 description 1
238000012737 microarray-based gene expression Methods 0.000 description 1
238000012243 multiplex automated genomic engineering Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000011518 platinum-based chemotherapy Methods 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000003757 reverse transcription PCR Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000010532 solid phase synthesis reaction Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
238000001890 transfection Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C12N9/1211—Thymidine kinase (2.7.1.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Pathology (AREA)
Hospice & Palliative Care (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Oncology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

JP2007531118A 2005-02-25 2006-02-17 Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン Expired - Fee Related JP4461179B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65685705P	2005-02-25	2005-02-25
PCT/JP2006/303354 WO2006090810A2 (en)	2005-02-25	2006-02-17	Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides

Related Child Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2009058801A Division JP2009173661A (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009058798A Division JP4493053B2 (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009058802A Division JP4493054B2 (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン

Publications (3)

Publication Number	Publication Date
JP2008530975A JP2008530975A (ja)	2008-08-14
JP2008530975A5 JP2008530975A5 (2)	2009-05-28
JP4461179B2 true JP4461179B2 (ja)	2010-05-12

Family

ID=36570330

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
JP2007531118A Expired - Fee Related JP4461179B2 (ja)	2005-02-25	2006-02-17	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009058798A Expired - Lifetime JP4493053B2 (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009058802A Expired - Lifetime JP4493054B2 (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009058801A Pending JP2009173661A (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009295766A Pending JP2010143924A (ja)	2005-02-25	2009-12-25	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
JP2009058798A Expired - Lifetime JP4493053B2 (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009058802A Expired - Lifetime JP4493054B2 (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009058801A Pending JP2009173661A (ja)	2005-02-25	2009-03-12	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
JP2009295766A Pending JP2010143924A (ja)	2005-02-25	2009-12-25	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン

Country Status (9)

Country	Link
US (2)	US7847060B2 (2)
EP (3)	EP2325305B1 (2)
JP (5)	JP4461179B2 (2)
DE (1)	DE602006021283D1 (2)
DK (2)	DK2325306T3 (2)
ES (3)	ES2364670T3 (2)
PL (2)	PL2325306T3 (2)
PT (2)	PT2325305E (2)
WO (1)	WO2006090810A2 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200413725A (en) *	2002-09-30	2004-08-01	Oncotherapy Science Inc	Method for diagnosing non-small cell lung cancers
EP2102360A2 (en) *	2006-12-13	2009-09-23	Oncotherapy Science, Inc.	Ttk as tumor marker and therapeutic target for lung cancer
AU2012261725B2 (en) *	2007-02-21	2014-11-27	Oncotherapy Science, Inc.	Peptide vaccines for cancers expressing tumor-associated antigens
TWI596109B (zh) *	2007-02-21	2017-08-21	腫瘤療法科學股份有限公司	表現腫瘤相關抗原之癌症的胜肽疫苗
WO2009016691A1 (en) *	2007-07-30	2009-02-05	Oncotherapy Science, Inc.	Cancer associated gene ly6k
CN101827936B (zh)	2007-08-20	2014-12-10	肿瘤疗法科学股份有限公司	Cdh3肽以及含有cdh3肽的药剂
TWI580431B (zh) *	2008-08-19	2017-05-01	腫瘤療法科學股份有限公司	Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
NZ592461A (en)	2008-10-22	2012-12-21	Oncotherapy Science Inc	Rab6kifl/kif20a epitope peptide and vaccines containing the same
TWI539160B (zh)	2008-12-05	2016-06-21	腫瘤療法科學股份有限公司	Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
BRPI0923402A2 (pt)	2008-12-24	2015-08-04	Oncotherapy Science Inc	Peptídeos c10rf59 e vacinas incluindo os mesmos.
BRPI1012312A2 (pt) *	2009-03-04	2017-03-21	Oncotherapy Science Inc	peptídeos vangl1 e vacinas incluindo os mesmos
TW201100090A (en) *	2009-04-01	2011-01-01	Oncotherapy Science Inc	C6orf167 peptides and vaccines containing the same
TW201102081A (en)	2009-05-11	2011-01-16	Oncotherapy Science Inc	TTK peptides and vaccines including the same
CA2773083C (en)	2009-09-03	2019-02-12	Toray Industries, Inc.	Immunity-inducing agent for prophylaxis or treatment of a pds5a-expressing cancer
TW201124530A (en) *	2009-12-01	2011-07-16	Oncotherapy Science Inc	IMP-3 oligopeptides and vaccines including the same
TW201200525A (en) *	2009-12-04	2012-01-01	Oncotherapy Science Inc	MYBL2 peptides and vaccines containing the same
TW201211250A (en) *	2010-09-07	2012-03-16	Oncotherapy Science Inc	VANGL1 peptides and vaccines including the same
US20150359864A1 (en)	2012-03-09	2015-12-17	Oncotherapy Science, Inc.	Pharmaceutical composition containing peptides
WO2014010232A1 (en) *	2012-07-10	2014-01-16	Oncotherapy Science, Inc.	Ly6k epitope peptides for th1 cells and vaccines containing the same
TWI643867B (zh)	2013-05-24	2018-12-11	日商腫瘤療法科學股份有限公司	對於ｔｈ１細胞之ｉｍｐ－３抗原決定位胜肽及含此之疫苗
EP3981416B1 (en)	2014-08-04	2024-03-20	OncoTherapy Science, Inc.	Koc1-derived peptide and vaccine including same
SG11201700838VA (en)	2014-08-04	2017-03-30	Oncotherapy Science Inc	Urlc10-derived peptide and vaccine containing same
JP6781508B2 (ja) *	2014-11-18	2020-11-04	塩野義製薬株式会社	安定化されたペプチド組成物
WO2021060343A1 (ja) *	2019-09-24	2021-04-01	オンコセラピー・サイエンス株式会社	Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en)	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
US5736524A (en)	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
US5922687A (en)	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
WO1997005900A1 (en)	1995-08-03	1997-02-20	Rijksuniversiteit Te Leiden	Cell derived antigen presenting vesicles
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja)	1996-07-26	2000-12-05	スローン―ケッタリングインスティチュートフォーキャンサーリサーチ	遺伝子的免疫化のための方法と試薬
AU723543B2 (en)	1997-04-07	2000-08-31	Roche Diagnostics Gmbh	Fanconi-gene II
WO1998045428A1 (de)	1997-04-07	1998-10-15	Roche Diagnostics Gmbh	Fanconi-gen ii
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6255055B1 (en)	1998-03-09	2001-07-03	Wisconsin Alumni Research Foundation	c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence
US20030236209A1 (en) *	1998-03-18	2003-12-25	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US20030045491A1 (en)	2001-02-23	2003-03-06	Christoph Reinhard	TTK in diagnosis and as a therapeutic target in cancer
WO2001072775A2 (en)	2000-03-29	2001-10-04	Diadexus, Inc.	Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
EP1474528A4 (en)	2000-10-13	2006-06-14	Protein Design Labs Inc	METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
AU2002220265A1 (en) *	2000-11-03	2002-05-15	University Of Vermont And State Agricultural College	Compositions for inhibiting grb7
KR100876327B1 (ko)	2001-02-21	2008-12-31	노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드	진단에서의, 그리고 암에서 치료 표적으로서의 ｔｔｋ
AU2002309583A1 (en)	2001-04-18	2002-11-05	Protein Desing Labs, Inc.	Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US7189507B2 (en) *	2001-06-18	2007-03-13	Pdl Biopharma, Inc.	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
MXPA04003382A (es)	2001-10-31	2004-11-22	Pfizer Prod Inc	Agentes terapeuticos y diagnostico para transtornos de la eritropoyesis.
EP1497454A2 (en)	2001-11-13	2005-01-19	Protein Design Labs, Inc.	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003042661A2 (en)	2001-11-13	2003-05-22	Protein Design Labs, Inc.	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en) *	2001-11-13	2003-12-18	Eos Biotechnology, Inc.	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
AU2003209340A1 (en)	2002-01-18	2003-09-02	Bristol-Myers Squibb Company	Predictor sets for tyrosine kinase pathways
ES2361541T3 (es) *	2002-06-06	2011-06-17	Oncotherapy Science, Inc.	Genes y polipéptidos relacionados con cánceres de colon humanos.
DE60327786D1 (de)	2002-09-12	2009-07-09	Oncotherapy Science Inc	Kdr-peptide und diese enthaltende impfstoffe
TW200413725A (en)	2002-09-30	2004-08-01	Oncotherapy Science Inc	Method for diagnosing non-small cell lung cancers
US20060024692A1 (en)	2002-09-30	2006-02-02	Oncotherapy Science, Inc.	Method for diagnosing non-small cell lung cancers
WO2005002509A2 (en)	2003-06-09	2005-01-13	Corixa Corporation	Dna vectors
JP4721903B2 (ja)	2004-01-29	2011-07-13	大日本住友製薬株式会社	新規腫瘍抗原蛋白質及びその利用
JP2005230011A (ja)	2004-02-20	2005-09-02	Samsung Electronics Co Ltd	乳ガン関連蛋白質、それをコーディングする遺伝子、及び該蛋白質及び該遺伝子を利用した乳ガンの診断方法
US7700573B2 (en)	2004-03-23	2010-04-20	Oncotherapy Science, Inc.	Method for diagnosing non-small lung cancer
CA2599875A1 (en)	2005-03-03	2006-09-08	Takeda Pharmaceutical Company Limited	Preventive/therapeutic agent for cancer
EP2102360A2 (en)	2006-12-13	2009-09-23	Oncotherapy Science, Inc.	Ttk as tumor marker and therapeutic target for lung cancer
WO2009016691A1 (en)	2007-07-30	2009-02-05	Oncotherapy Science, Inc.	Cancer associated gene ly6k
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same

2006
- 2006-02-17 ES ES06714493T patent/ES2364670T3/es not_active Expired - Lifetime
- 2006-02-17 EP EP10010438.9A patent/EP2325305B1/en not_active Expired - Lifetime
- 2006-02-17 JP JP2007531118A patent/JP4461179B2/ja not_active Expired - Fee Related
- 2006-02-17 EP EP06714493A patent/EP1853703B1/en not_active Expired - Lifetime
- 2006-02-17 US US11/816,616 patent/US7847060B2/en not_active Expired - Lifetime
- 2006-02-17 WO PCT/JP2006/303354 patent/WO2006090810A2/en not_active Ceased
- 2006-02-17 PT PT100104389T patent/PT2325305E/pt unknown
- 2006-02-17 DE DE602006021283T patent/DE602006021283D1/de not_active Expired - Lifetime
- 2006-02-17 DK DK10010439.7T patent/DK2325306T3/en active
- 2006-02-17 ES ES10010438.9T patent/ES2459492T3/es not_active Expired - Lifetime
- 2006-02-17 DK DK10010438.9T patent/DK2325305T3/en active
- 2006-02-17 PL PL10010439T patent/PL2325306T3/pl unknown
- 2006-02-17 PL PL10010438T patent/PL2325305T3/pl unknown
- 2006-02-17 EP EP10010439.7A patent/EP2325306B1/en not_active Expired - Lifetime
- 2006-02-17 PT PT100104397T patent/PT2325306E/pt unknown
- 2006-02-17 ES ES10010439.7T patent/ES2459466T3/es not_active Expired - Lifetime
2009
- 2009-03-12 JP JP2009058798A patent/JP4493053B2/ja not_active Expired - Lifetime
- 2009-03-12 JP JP2009058802A patent/JP4493054B2/ja not_active Expired - Lifetime
- 2009-03-12 JP JP2009058801A patent/JP2009173661A/ja active Pending
- 2009-12-25 JP JP2009295766A patent/JP2010143924A/ja active Pending
2010
- 2010-10-13 US US12/903,961 patent/US8614176B2/en active Active

Also Published As

Publication number	Publication date
WO2006090810A3 (en)	2007-03-29
ES2459466T3 (es)	2014-05-09
JP2010143924A (ja)	2010-07-01
JP2009173662A (ja)	2009-08-06
JP2009173661A (ja)	2009-08-06
JP4493054B2 (ja)	2010-06-30
US7847060B2 (en)	2010-12-07
EP2325305A1 (en)	2011-05-25
EP2325306B1 (en)	2014-02-12
EP1853703A2 (en)	2007-11-14
US20090202576A1 (en)	2009-08-13
EP2325306A1 (en)	2011-05-25
EP1853703B1 (en)	2011-04-13
WO2006090810A2 (en)	2006-08-31
ES2364670T3 (es)	2011-09-12
JP2009173660A (ja)	2009-08-06
DK2325305T3 (en)	2014-03-03
ES2459492T3 (es)	2014-05-09
EP2325305B1 (en)	2014-02-12
JP2008530975A (ja)	2008-08-14
PL2325306T3 (pl)	2014-07-31
US20110027302A1 (en)	2011-02-03
DK2325306T3 (en)	2014-03-03
JP4493053B2 (ja)	2010-06-30
HK1156076A1 (en)	2012-06-01
PT2325305E (pt)	2014-04-29
US8614176B2 (en)	2013-12-24
PL2325305T3 (pl)	2014-07-31
DE602006021283D1 (de)	2011-05-26
HK1156077A1 (en)	2012-06-01
PT2325306E (pt)	2014-04-29

Legal Events

Date	Code	Title	Description
2008-07-12	A711	Notification of change in applicant	Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080711
2008-07-31	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080730
2008-08-09	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080711
2008-10-18	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081017
2008-10-18	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20081017
2009-02-03	A524	Written submission of copy of amendment under article 19 pct	Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090202
2009-03-13	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090312
2009-04-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090312
2009-10-06	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091005
2009-12-03	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091202
2010-01-13	TRDD	Decision of grant or rejection written
2010-01-19	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100118
2010-01-21	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01
2010-02-18	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100215
2010-02-19	R150	Certificate of patent or registration of utility model	Ref document number: 4461179 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150
2010-02-22	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130219 Year of fee payment: 3
2010-05-12	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130219 Year of fee payment: 3
2012-06-21	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130219 Year of fee payment: 3
2012-11-07	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130219 Year of fee payment: 3
2012-12-20	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20130219 Year of fee payment: 3
2013-01-22	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20140219 Year of fee payment: 4
2013-01-22	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2014-01-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2015-01-27	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2016-01-26	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2017-01-24	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2018-01-23	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2019-01-22	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2020-01-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-01-21	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-01-20	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-02-25	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-03-02	S531	Written request for registration of change of domicile	Free format text: JAPANESE INTERMEDIATE CODE: R313531
2023-03-10	R350	Written notification of registration of transfer	Free format text: JAPANESE INTERMEDIATE CODE: R350
2024-02-19	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP4493054B2 (ja)	2010-06-30	Ｔｔｋ、ｕｒｌｃ１０、またはｋｏｃ１ポリペプチドを発現する肺癌に対するペプチドワクチン
CN101568550B (zh)	2012-12-26	用于表达mphosph1或depdc1多肽的癌症的肽疫苗
TWI615403B (zh)	2018-02-21	表現腫瘤相關抗原之癌症的胜肽疫苗
HK1156076B (en)	2014-05-30	Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
HK1156077B (en)	2014-05-30	Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
HK1171024B (en)	2015-11-20	Peptide vaccines for cancers expressing mphosph1 polypeptides
HK1171026B (en)	2015-11-20	Peptide vaccines for cancers expressing depdc1 polypeptides
HK1171025B (en)	2015-11-20	Peptide vaccines for cancers expressing depdc1 polypeptides